FLT3 and acute myeloid leukemia: Although the results reported here and elsewhere [13] indicate quantitative increases in DSB frequencies per cell in treated FLT3-ITD AML cells, the genome-wide profiles of DSB enrichment are qualitative and therefore cannot be used to directly compare DSBs in cells treated with daunorubicin alone to cells co-treated with AZD1208.